• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

    6/30/25 11:05:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZEAL alert in real time by email

    Company announcement – No. 16 / 2025

    Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

    Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred.

    In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of June 30, 2025.



     



    Date
    Number of shares

    (nominal value of DKK 1 each)
    Share capital

    (nominal value in DKK)
    Number of voting rights
    June 30, 202571,343,80471,343,80471,343,804

    The Company's Articles of Association are available on the Company's website https://www.zealandpharma.com.

    # # #

    About Zealand Pharma A/S

    Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products.

    Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit www.zealandpharma.com.

    Contact

    Adam Lange (Investors)

    Vice President, Investor Relations

    [email protected]

    Neshat Ahmadi (Investors)

    Investor Relations Manager

    [email protected]

    Anna Krassowska (Investors and Media)

    Vice President, Investor Relations & Corporate Communications

    [email protected]



    Primary Logo

    Get the next $ZEAL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZEAL

    DatePrice TargetRatingAnalyst
    3/5/2024Buy
    Berenberg
    8/8/2023Equal-Weight
    Morgan Stanley
    11/16/2022Overweight → Equal-Weight
    Morgan Stanley
    1/11/2022Hold → Buy
    Jefferies
    More analyst ratings

    $ZEAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zealand Pharma to participate in upcoming investor conferences in September 2025

    Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investor Relations, will host investor meetings on Wednesday, September 3. Cantor Global Healthcare Conference 2025, September 3-5 in New York Adam Steensberg, President and Chief Executive

    8/28/25 11:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

    Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.97

    8/20/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on Zealand Pharma

    Berenberg initiated coverage of Zealand Pharma with a rating of Buy

    3/5/24 7:30:01 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Zealand Pharma

    Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight

    8/8/23 7:40:54 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma downgraded by Morgan Stanley

    Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight

    11/16/22 9:37:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    SEC Filings

    View All

    SEC Form 15F-12B filed by Zealand Pharma A/S

    15F-12B - Zealand Pharma A/S (0001674988) (Filer)

    9/30/22 5:24:36 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:20:13 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:16:47 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Leadership Updates

    Live Leadership Updates

    View All

    Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

    Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog

    5/19/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

    Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)

    4/23/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

    Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades

    11/30/23 2:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Financials

    Live finance-specific insights

    View All

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

    Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall;

    8/7/25 11:30:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma increases its share capital as a result of the exercise of employee warrants

    Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

    6/6/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zealand Pharma A/S (Amendment)

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/14/22 12:27:01 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/3/21 1:13:21 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care